Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • ElenaN
    Junior Member
    • Nov 2012
    • 8

    VarScan: somatic mutations in heterozygous sites?

    Does VarScan2 find somatic mutations that arose in loci where norm was heterozygous? As far as I can tell, it classifies somatic changes as "Somatic" (but that seems to only include homozygous normal) and "loss of heterozygosity", where normal was hetereozygous, and tumor is homozygous". What happens if normal was heterozygous, and tumor has 3 alleles (one novel)? I don't seem to be able to find such sites in VarScan output.
    Thank you,
    Elena
  • dkoboldt
    Member
    • Mar 2009
    • 62

    #2
    Are there situations where true, validated somatic mutations arise at the position of heterozygous SNPs? My expectation is that most such situations would represent artifactual calls, not real events.

    In your example, the normal would be called heterozygous, and the tumor would be called heterozygous (if a variant allele met calling criteria). The most-supported variant allele in tumor would be taken as the consensus. If it's the same as the normal variant allele, the call will be Germline. If it's a third allele, VarScan will call it "Unknown" because this is an unexpected situation. Running VarScan somatic with the --validation 1 parameter will tell you.

    You could also investigate by running VarScan mpileup2cns instead. Feel free to e-mail me the pileup outputs if you'd like to discuss further.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    213 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    79 views
    0 reactions
    Last Post SEQadmin2  
    Working...